For the quarter ending 2026-03-31, CORT had -$11,757K decrease in cash & cash equivalents over the period. -$16,973K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | - | 99,652 | - | - |
| Net (loss) income | -107,125 | - | 19,668 | 55,696 |
| Accrued settlement related to melucci litigation (note 10) | - | 0 | 0 | 0 |
| Stock-based compensation | 23,043 | 20,768 | 22,879 | 40,853 |
| Accrued research and development expenses | - | 5,632 | -727 | -4,819 |
| Accretion of discount on marketable securities, net | - | 5,103 | - | - |
| Accretion of marketable securities, net | 3,174 | - | -1,005 | -3,005 |
| Depreciation and amortization | 598 | 289 | 289 | 571 |
| Insurance recovery receivable related to melucci litigation (note 10) | - | 0 | 0 | 0 |
| Deferred income taxes | -13,110 | -15,182 | 9,114 | -31,469 |
| Long-term accrued income taxes | - | 1,044 | -1,545 | 1,593 |
| Amortization of right-of-use asset | - | 193 | 188 | 360 |
| Operating lease liability | - | -251 | -247 | -331 |
| Trade receivables | -20,714 | -9,843 | 5,062 | 10,591 |
| Inventory | 3,272 | -483 | 3,943 | 4,021 |
| Prepaid expenses and other current assets | -4,736 | 3,224 | 13,461 | 2,232 |
| Other assets | - | -2,896 | -254 | 1,693 |
| Accounts payable | -7,644 | 5,998 | 10,921 | 8,149 |
| Accrued research and development expenses | 137 | - | - | - |
| Accrued and other liabilities, current and non-current | -9,377 | -13,236 | 17,158 | 6 |
| Net cash (used in) provided by operating activities | -16,772 | 38,448 | 54,481 | 49,067 |
| Purchases of property and equipment | 201 | 50 | 0 | 161 |
| Proceeds from sales and maturities of marketable securities | 57,071 | 132,040 | 52,000 | 205,536 |
| Purchases of marketable securities | 52,328 | 143,833 | 37,355 | 138,419 |
| Net cash provided by (used in) investing activities | 4,542 | -11,843 | 14,645 | 66,956 |
| Proceeds from stock option exercises, net of issuance costs | 3,984 | 2,861 | 2,033 | 10,975 |
| Proceeds from purchases under the employee stock purchase program | 2,537 | 2,461 | 2,170 | 4,990 |
| Repurchases of common stock in connection with stock repurchase program | 0 | 0 | 42,464 | 130,451 |
| Repurchase of common stock in connection with tender offer | - | 0 | - | - |
| Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants | 5,761 | 36,538 | 8,152 | 28,251 |
| Net cash provided by (used in) financing activities | 760 | -31,216 | -46,413 | -142,737 |
| Net effect of exchange rate changes on cash, cash equivalents and restricted cash | -287 | -32 | -320 | 1,794 |
| Net decrease in cash, cash equivalents and restricted cash | -11,757 | -4,643 | 22,393 | -24,920 |
| Cash, cash equivalents and restricted cash, at beginning of period | 121,745 | 125,138 | 127,665 | - |
| Cash, cash equivalents and restricted cash, at end of period | 109,988 | 120,495 | 125,138 | - |
CORCEPT THERAPEUTICS INC (CORT)
CORCEPT THERAPEUTICS INC (CORT)